{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.68","upperLimit":"3.06","value":"1.87"},{"groupId":"OG001","lowerLimit":"1.81","upperLimit":"3.68","value":"1.94"},{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"1.41","upperLimit":"NA","value":"1.87"},{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG003","lowerLimit":"1.64","upperLimit":"NA","value":"3.02"},{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG004","lowerLimit":"1.64","upperLimit":"NA","value":"3.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Time to progression (TTP) was defined as the time from Cycle 1 Day 1 to the earliest date of radiographic disease progression per RECIST 1.1, or if the subject did not experience disease progression, to the last imaging assessment. TTP was analyzed using the K-M method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Metastatic colorectal cancer (CRC) defined as histologically and/or cytologically confirmed CRC, and must have received at least 1 prior regimen for advanced/metastatic disease.","id":"OG000","title":"Colorectal Cancer"},{"description":"High grade serous ovarian cancer (HGSOC) defined as histologically confirmed high grade serous ovarian, fallopian tube or primary peritoneal cancer who were recurrent platinum intolerant, or with platinum resistant disease defined as radiological evidence of disease progression within 6 months of the last receipt of platinum based chemotherapy.","id":"OG001","title":"High Grade Serous Ovarian Cancer"},{"description":"Advanced non small cell lung cancer (NSCLC) defined as locally advanced and recurrent or metastatic, histologically confirmed NSCLC, and must have received at least 1 prior regimen for advanced/metastatic disease.","id":"OG002","title":"Non Small Cell Lung Cancer"},{"description":"Metastatic castration resistant prostate cancer (mCRPC) defined as histologically or cytologically confirmed adenocarcinoma of the prostate that has progressed after androgen deprivation therapy.","id":"OG003","title":"Metastatic Other Tumor Type Castration Resistant Prostate Cancer"},{"description":"Histologically confirmed HNSCC from any primary site; locally advanced disease (ie, persistent or progressive disease following curative intent radiation, and not a candidate for surgical salvage due to incurability or morbidity), or metastatic disease.","id":"OG004","title":"Head and Neck Squamous Cell Carcinoma"}],"paramType":"MEDIAN","populationDescription":"The Response Evaluable Population (REP) included all enrolled subjects who satisfy all of the following conditions:\n\n1. Measurable disease and assessment at baseline\n2. Received at least 75% of 1 cycle of study medication, based on dosing information\n3. At least one post baseline disease assessment OR discontinued treatment due to AE or disease progression or death","reportingStatus":"POSTED","timeFrame":"Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.","title":"Time to Progression (TTP)","type":"PRIMARY","unitOfMeasure":"months"}